Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

China’s National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 ...

The Food and Drug Administration (FDA) approved Wegovy (semaglutide) in 2021 for chronic (long-term) weight management.In 2024, the FDA approved the drug for an additional use: to reduce the risk ...

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 ...